Tags

Type your tag names separated by a space and hit enter

Evaluation of an extensively hydrolysed casein formula (Damira 2000) in children with allergy to cow's milk proteins.
Allergol Immunopathol (Madr). 2010 Mar-Apr; 38(2):60-8.AI

Abstract

OBJECTIVE

To assess the allergenic capacity of a new extensively hydrolysed casein formula (Damira 2000) in vivo in children with allergy to cow's milk, and to conduct an immunochemical evaluation of the product.

PATIENTS AND METHODS

The study comprised 67 children (1 month-7 years) with allergy to cow's milk proteins (ACMP). Skin testing was made with whole milk, milk formula for infants, the study hydrolysate and the milk fractions (alpha-lactoalbumin, beta-lactoglobulin and casein). Specific IgE against these allergens, and oral provocation test were also performed. Immunochemical evaluation of the product was carried out with gel filtration chromatography, 4-15% acrylamide gradient gel electrophoresis, specific IgE quantification versus the casein hydrolysate and a study of its allergenic potency.

RESULTS

The hydrolysate was tolerated by 66 of the 67 patients (98.5%) with ACMP. Biochemical analysis of the product confirmed the absence of traces of whole milk proteins. Specific IgE against the hydrolysate proved negative in all cases, and it was unable to inhibit FEIA even at concentrations 10 times greater than those used in the whole milk inhibition control. Likewise, no immunoblotting inhibition was recorded.

CONCLUSIONS

The new extensively hydrolysed casein product is safe and well tolerated by most children with ACMP. However, as with other extensive hydrolysates, some highly sensitised patients may present clinical manifestations. Controlled tolerance testing is therefore advised, under specialised medical supervision.

Authors+Show Affiliations

Allergy Unit, Terrassa Hospital, Terrassa, Barcelona, Spain. marcel_ibero@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20015589

Citation

Ibero, M, et al. "Evaluation of an Extensively Hydrolysed Casein Formula (Damira 2000) in Children With Allergy to Cow's Milk Proteins." Allergologia Et Immunopathologia, vol. 38, no. 2, 2010, pp. 60-8.
Ibero M, Boné J, Martín B, et al. Evaluation of an extensively hydrolysed casein formula (Damira 2000) in children with allergy to cow's milk proteins. Allergol Immunopathol (Madr). 2010;38(2):60-8.
Ibero, M., Boné, J., Martín, B., & Martínez, J. (2010). Evaluation of an extensively hydrolysed casein formula (Damira 2000) in children with allergy to cow's milk proteins. Allergologia Et Immunopathologia, 38(2), 60-8. https://doi.org/10.1016/j.aller.2009.08.001
Ibero M, et al. Evaluation of an Extensively Hydrolysed Casein Formula (Damira 2000) in Children With Allergy to Cow's Milk Proteins. Allergol Immunopathol (Madr). 2010 Mar-Apr;38(2):60-8. PubMed PMID: 20015589.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of an extensively hydrolysed casein formula (Damira 2000) in children with allergy to cow's milk proteins. AU - Ibero,M, AU - Boné,J, AU - Martín,B, AU - Martínez,J, Y1 - 2009/12/16/ PY - 2009/06/23/received PY - 2009/08/25/accepted PY - 2009/12/18/entrez PY - 2009/12/18/pubmed PY - 2010/8/25/medline SP - 60 EP - 8 JF - Allergologia et immunopathologia JO - Allergol Immunopathol (Madr) VL - 38 IS - 2 N2 - OBJECTIVE: To assess the allergenic capacity of a new extensively hydrolysed casein formula (Damira 2000) in vivo in children with allergy to cow's milk, and to conduct an immunochemical evaluation of the product. PATIENTS AND METHODS: The study comprised 67 children (1 month-7 years) with allergy to cow's milk proteins (ACMP). Skin testing was made with whole milk, milk formula for infants, the study hydrolysate and the milk fractions (alpha-lactoalbumin, beta-lactoglobulin and casein). Specific IgE against these allergens, and oral provocation test were also performed. Immunochemical evaluation of the product was carried out with gel filtration chromatography, 4-15% acrylamide gradient gel electrophoresis, specific IgE quantification versus the casein hydrolysate and a study of its allergenic potency. RESULTS: The hydrolysate was tolerated by 66 of the 67 patients (98.5%) with ACMP. Biochemical analysis of the product confirmed the absence of traces of whole milk proteins. Specific IgE against the hydrolysate proved negative in all cases, and it was unable to inhibit FEIA even at concentrations 10 times greater than those used in the whole milk inhibition control. Likewise, no immunoblotting inhibition was recorded. CONCLUSIONS: The new extensively hydrolysed casein product is safe and well tolerated by most children with ACMP. However, as with other extensive hydrolysates, some highly sensitised patients may present clinical manifestations. Controlled tolerance testing is therefore advised, under specialised medical supervision. SN - 1578-1267 UR - https://www.unboundmedicine.com/medline/citation/20015589/Evaluation_of_an_extensively_hydrolysed_casein_formula__Damira_2000__in_children_with_allergy_to_cow's_milk_proteins_ L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0301-0546(09)00047-0 DB - PRIME DP - Unbound Medicine ER -